- Home
- RVNC vs VNDA Comparison
RVNC vs VNDA Comparison
Compare RVNC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- VNDA
- Stock Information
- Founded
- RVNC 1999
- VNDA 2002
- Country
- RVNC United States
- VNDA United States
- Employees
- RVNC N/A
- VNDA N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- RVNC Health Care
- VNDA Health Care
- Exchange
- RVNC Nasdaq
- VNDA Nasdaq
- Market Cap
- RVNC 546.4M
- VNDA 270.2M
- IPO Year
- RVNC 2014
- VNDA 2006
- Fundamental
- Price
- RVNC $5.29
- VNDA $4.73
- Analyst Decision
- RVNC Buy
- VNDA Buy
- Analyst Count
- RVNC 10
- VNDA 1
- Target Price
- RVNC $10.86
- VNDA $13.00
- AVG Volume (30 Days)
- RVNC 1.3M
- VNDA 641.3K
- Earning Date
- RVNC 11-06-2024
- VNDA 11-06-2024
- Dividend Yield
- RVNC N/A
- VNDA N/A
- EPS Growth
- RVNC N/A
- VNDA N/A
- EPS
- RVNC N/A
- VNDA N/A
- Revenue
- RVNC $251,178,000.00
- VNDA $182,022,000.00
- Revenue This Year
- RVNC $20.36
- VNDA $6.70
- Revenue Next Year
- RVNC $31.66
- VNDA $51.03
- P/E Ratio
- RVNC N/A
- VNDA N/A
- Revenue Growth
- RVNC 40.23
- VNDA N/A
- 52 Week Low
- RVNC $2.30
- VNDA $3.30
- 52 Week High
- RVNC $9.75
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- RVNC 44.50
- VNDA 48.57
- Support Level
- RVNC $5.10
- VNDA $4.68
- Resistance Level
- RVNC $5.43
- VNDA $4.98
- Average True Range (ATR)
- RVNC 0.17
- VNDA 0.18
- MACD
- RVNC 0.02
- VNDA 0.05
- Stochastic Oscillator
- RVNC 66.67
- VNDA 40.00
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.